Tuesday, August 29, 2023
Empyrean Medical Systems, MagCorp, and MetOx Technologies have come together in a strategic collaboration aimed at accelerating the development of advanced technology for radiation therapy in cancer treatment. This collaboration seeks to enable the large-scale production of innovative radiation therapy systems for commercial use. MagCorp's expertise in superconducting magnet technology, combined with MetOx's cutting-edge High-Temperature Superconducting wire (HTS), will be harnessed to create state-of-the-art radiation therapy technology for Empyrean.
Empyrean's Morpheus™ beam sculpting image-guided radiotherapy system, which has rapidly progressed from concept to FDA clearance in less than eighteen months, is now gearing up for mass production. The successful implementation of this collaboration holds significant promise for the future of cancer treatment, addressing the growing global demand for advanced solutions. HTS technology plays a pivotal role, driving scientific and engineering advancements, enhancing product sophistication, and pushing the boundaries of multiple fields.
This partnership aligns Empyrean's scientific, engineering, and business teams with MagCorp's collaborative efforts. Notably, experts from the National High Magnetic Field Laboratory in Tallahassee, FL, specializing in HTS superconducting magnet technology, contribute their expertise. The availability of HTS at a larger scale had been a missing piece in fully leveraging this technology's potential.
Together, MagCorp, MetOx, and Empyrean constitute a think tank of innovative minds essential for overcoming challenges and reshaping cancer treatment technologies. MetOx's scalability in technology further contributes to advancements in medical diagnostics and treatment. The utilization of HTS is pivotal in generating the necessary high magnetic fields for this transformative approach.
Source: prnewswire.com
